|
2. Etiologie
|
|
|
Invoking cancer and stress in the same breath is not the same as blaming the victim [The Guardian]
|
|
|
|
|
|
Their
work, published in the prestigious journal, Nature Communications,
showed that chronic stress in mice remodels the lymphatic system,
enlarging the calibre of the vessels as well as the rate of flow through
them, therefore enhancing the spread of tumour cells from an existing
tumour. It’s important to note that their research doesn’t suggest that
stress causes a primary cancer to develop.
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
The Supreme Court decision that’s shaking up biotech [STAT]
|
|
|
|
|
|
The
justices spooked the industry by declining to hear an appeal from
Sequenom, a California company that markets a prenatal test based on
screening fetal DNA. A lower court had ruled that Sequenom couldn’t
patent the test because it was based on a natural biological process.
|
|
|
|
|
|
|
Pfizer to invest $350 million in China biotech hub, first in Asia [Reuters]
|
|
|
|
|
|
Global
"Big Pharma" is increasingly looking for smart ways to tap China's
healthcare market, estimated by consultancy IMS Health to be worth
around $185 billion by 2018. From investing in China facilities to
acquisitions, licensing deals and joint ventures, the aim is to seek an
edge in dealings with domestic regulators and government.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
5.5 ASCO
|
|
|
|
6. Lutte contre les cancers
|
|
|
Well: Putting Breast Cancer on a Diet [NY Times]
|
|
|
|
|
|
Scientists
are recruiting thousands of women for a large clinical trial to find
out. The plan is to put heavy women age 18 and older who were recently
given diagnoses of breast cancer on diets to see if losing weight will
keep their cancer from coming back.
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
Martin McKee: Brexit and health—the confusion grows [BMJ Blogs]
|
|
|
|
|
|
What
is certain is that, in these circumstances, those pharmaceutical
companies that have invested in the UK, at least in part because of the
location of the EMA in London, will be very unlikely to plan any further
investment in the UK. But then it seems that no-one is planning to
invest here now.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
|